In recent developments for Avidity Biosciences (RNA, Financial), Cantor Fitzgerald has decided to maintain its positive outlook on the company. Analyst Eric Schmidt reiterated an "Overweight" rating for RNA, with no changes in the price target, which remains at $96.00 USD.
The decision by Cantor Fitzgerald to sustain both the rating and price target underlines their continued confidence in Avidity Biosciences' market potential. As of June 27, 2025, the financial institution did not report any percentage change in the price target, indicating a stable outlook for the company's stock performance.
Avidity Biosciences (RNA, Financial) continues to attract attention from investors, with the reiteration of its "Overweight" rating suggesting anticipated growth or positive future performance. Stakeholders and market participants are likely to keep a close watch on the company's upcoming developments, given Cantor Fitzgerald's maintained confidence in the stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Avidity Biosciences Inc (RNA, Financial) is $65.81 with a high estimate of $96.00 and a low estimate of $50.00. The average target implies an upside of 120.63% from the current price of $29.83. More detailed estimate data can be found on the Avidity Biosciences Inc (RNA) Forecast page.
Based on the consensus recommendation from 16 brokerage firms, Avidity Biosciences Inc's (RNA, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Avidity Biosciences Inc (RNA, Financial) in one year is $10.43, suggesting a downside of 65.04% from the current price of $29.83. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Avidity Biosciences Inc (RNA) Summary page.
